Aga Khan University
Karachi, Pakistan
NCT Number: NCT00125047
This study is part of the International Vaccine Institute's (IVI's) typhoid Vi demonstration project that aims to accelerate the rational introduction of Vi vaccines in typhoid endemic countries. The purpose of this study is to determine the effectiveness of the Vi vaccine following a mass typhoid immunization campaign in an endemic area in Karachi, Pakistan. The cost-effectiveness of Vi vaccination and the logistic feasibility of a mass typhoid immunization campaign will also be evaluated.
Looking for future studies?
Notify Me2 year–16 year
All sexes
Interventional
Phase 4
Karachi, Pakistan
Typhoid fever is a major cause of morbidity worldwide. The disease predominantly affects school-aged children, is more prevalent in urban areas, may last for several weeks and can lead to serious complications. Management of this disease is further complicated by the emergence of multi-drug resistant strains. Vaccination of high risk populations is considered the most promising strategy for the control of typhoid fever. The Vi polysaccharide vaccine has been targeted for accelerated introduction into public health programs due to the following reasons: it has been shown to have consistent efficacy results even in areas of high typhoid incidence; is given as a single dose; lacks patent protection and requires less strict cold chain requirements. A cluster-randomized trial involving the Vi polysaccharide vaccine and an active control (hepatitis A) was designed to determine the effectiveness and the feasibility of providing Vi vaccine under actual programmatic conditions in 3 urban slums in Pakistan. The vaccines used in this study are internationally produced and locally licensed. A complimentary, targeted, basic typhoid prevention health education program for the entire population at the initiation of the project will be provided and the actual Vi-demonstration project will be preceded by a 12-month typhoid surveillance activity.
Secondary objectives of this trial are:
A nested, prospective matched case-control study is included in the trial in order to study typhoid risk factors among children in Karachi.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Single 0.5ml dose containing 25ug purified Vi polysaccharide of S. typhi.
Other names: Typherix
single 0.5ml dose contains 720 EL.U. of inactivated hepatitis A viral antigen
Other names: Havrix
Time frame: 2 years from zero time
Time frame: two years from zero time
Time frame: 2 years from zero time
Time frame: 30 days from vaccination
International Vaccine Institute
Other
Effectiveness of a Combined Vi Vaccination and Health Education Program on Reducing the Burden of Typhoid During Childhood: A Demonstration Project in Karachi
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT00125008
Bacterial Infections, Bacterial Infections and Mycoses
Kolkata, West Bengal, India
View Trial DetailsNCT00131833
Bacterial Infections, Bacterial Infections and Mycoses
Hechi, Guangxi, China
View Trial DetailsNCT00131820
Bacterial Infections, Bacterial Infections and Mycoses
Hanoi, Vietnam
View Trial DetailsNCT04878549
Acute Febrile Illness, Bacterial Infections
Vellore, India
View Trial Details